Menarini Group

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Menarini Group sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 7 completed early-phase tilt top decile by trial count

Menarini Group: 9 sponsored US clinical trials, none currently recruiting.

Menarini Group sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 2 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Colic, with 1 trials.

Top-decile sponsor footprint

Menarini Group ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

How the Menarini Group early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 7 completed (78%).

Phase mix: 2 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Colic (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Menarini Group: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Menarini Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Menarini Group4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Menarini Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Menarini Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Menarini Group page

9 registered trials is a research-attention snapshot, not an endorsement of Menarini Group or any single study.

  • None of Menarini Group's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Colic is the condition Menarini Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Colic trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Menarini Group pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.